June 16, 2023
2 min watch
Save
VIDEO: New CAR T-cell therapies ‘waiting in the wings’ for patients with leukemia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Eunice Wang, MD, discussed an abstract relating to new chimeric antigen receptor T-cell therapies treating acute lymphocytic leukemia, presented at ASCO Annual Meeting.
Wang, chief of the leukemia service at Roswell Park Comprehensive Cancer Center, highlighted data regarding the effectiveness of obecabatagene autoleucel (AUTO1; Autolus Therapeutics) — also known as obe-cel — therapy, which she said showed a very promising outlook for its role in treating ALL.
“That study is still in early development, but did suggest that newer, better CARs — a new line of CARS — may be waiting in the wings for our patients,” Wang said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Wang reports consulting, advising and speaking for AbbVie, Amgen, Astellas, Bristol Myers Squibb, CTI Biopharm, Daiichi Sankyo, Gilead, GSK, Janssen, Jazz Pharmaceuticals, Kite Pharma, Kura Oncology, Novartis, Pfizer, PharmaEssentia, Rigel, Sellas, Stemline and Sumitomo Pharma.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.